Related by context. All words. (Click for frequent words.) 84 mg m 78 mcg kg 78 #mg/m# [002] 78 mg/m2/day 77 #mg/m# [001] 74 mg m² 74 mg kg 71 mg BID 71 mg QD 68 ug kg 68 μg dose 68 mg/m2 dose 68 #mg/kg [002] 67 Q2W 67 administered subcutaneously 67 mg TID 67 mg/m2 administered 67 mg kg dose 67 mg/m2 IV 66 lopinavir r 66 mg d 66 ascending doses 66 q#h 66 4mg/kg 66 8mg/kg 65 mg qd 65 CIMZIA TM 65 mcg 65 #mg QD [002] 65 Peg IFN 65 dosing cohorts 65 pegylated interferon alfa 2a 65 mg dose 64 mg orally 64 mCi kg 64 FOLFOX 64 mg eq 64 mcg dose 64 continuous intravenous infusion 64 subcutaneous dose 64 mcg albinterferon alfa 2b 64 plus ribavirin 64 μg 64 subcutaneous doses 64 evaluable 64 docetaxel 63 mitoxantrone 63 fluorouracil 63 mg 63 peginterferon alfa 2a 63 mg q8h 63 administered orally 63 mg kg IV 63 mcg BID 63 doxorubicin cyclophosphamide 63 interferon alfa 2a 63 mg kg hr 63 evaluable patients 63 piperacillin tazobactam 63 intramuscularly 63 telaprevir dosed 63 ascending dose 63 μg kg 63 dose regimens 63 carboplatin 63 mg subcutaneously 62 progression TTP 62 subcutaneously 62 ribavirin RBV 62 docetaxel chemotherapy 62 achieved ACR# 62 nab paclitaxel 62 q8h 62 saline placebo 62 FOLFIRI 62 Median survival 62 mg subcutaneous injection 62 #mg q8h 62 Locteron administered 62 intermittent dosing 62 achieved PASI 62 dose cohorts 62 kBq kg 62 mg administered orally 62 subcutaneous SC 61 #mg BID [001] 61 carboplatin AUC 6 61 carboplatin paclitaxel 61 Pegasys ® 61 ng dL 61 IV bolus 61 alfa 2a 61 dose cohort 61 cyclophosphamide 61 dosing cohort 61 estramustine 61 mcg mL 61 lopinavir r arm 61 plus prednisone 61 mg/# hr 61 VELCADE melphalan 61 mg iv peramivir 61 microgram kg 61 REYATAZ r 61 median PFS 61 mitomycin 61 LEXIVA r 61 mCi m 2 61 #mg QD [001] 61 IU ml 61 dose limiting toxicities 61 q#d 61 chlorambucil 61 DLTs 61 PREZISTA r 61 3mg/kg 60 monotherapy 60 tolerated dose MTD 60 FOLPI 60 mg RDEA# 60 oral prednisone 60 placebo intravenously 60 intravenous bolus 60 evaluable subjects 60 peginterferon alfa 2b 60 dacarbazine 60 daunorubicin 60 PEG IFN 60 FOLPI regimen 60 mcg doses 60 dosed orally 60 intravenous infusion 60 peg IFN 60 telaprevir dosing 60 intravenous REOLYSIN 60 pg mL 60 febrile neutropenia 60 biochemical relapse 60 #mg BID [003] 60 comparator arm 60 melphalan 60 ritonavir boosted 60 intravenous picoplatin 60 RECIST criteria 60 adalimumab 60 PREZISTA ritonavir 60 randomized #:# 60 QD dosing 60 gemcitabine 60 dexamethasone 60 Pegasys plus Copegus 60 mcg Albuferon 60 subcutaneous injections 59 injected subcutaneously 59 etanercept 59 n = 59 mCi 59 timepoints 59 severe neutropenia 59 q# 59 vinorelbine 59 idarubicin 59 FOLFOX4 alone 59 #ug [001] 59 FOLFOX6 59 plus methotrexate 59 mg ustekinumab 59 cytarabine daunorubicin 59 #mg BID [002] 59 subcutaneous enoxaparin 59 #.#mg/kg [002] 59 CHOP chemotherapy 59 daily Infergen 59 relapsed MM 59 PEGASYS ® 59 FOLFOX4 59 APTIVUS r 59 undetectable HCV RNA 59 abacavir lamivudine 59 log# 59 IU mL 59 relapsed refractory multiple myeloma 59 μg doses 59 certolizumab 59 rapid virologic response 59 Median progression 59 stage IIIB 59 REYATAZ r arm 59 CCyR 59 rFSH 59 dose escalation 59 melphalan prednisone 59 HBeAg seroconversion 59 interferon alfa 59 partial remissions 59 subcutaneous injection 59 #mg [003] 59 #μg [002] 59 mg kg REMICADE 59 titrated 59 ARIKACE 59 5 fluorouracil 59 #mg/day [002] 59 #mg/day [001] 58 subcutaneously administered 58 timepoint 58 ZALBIN dosed 58 epoetin alfa 58 plasma uric acid 58 cGy 58 TAXOTERE R 58 Folfox 58 #μg [001] 58 blinded randomized placebo controlled 58 refractory NSCLC 58 bortezomib 58 dosage regimens 58 intravitreal injection 58 microg 58 Bezielle 58 weekly intravenous infusions 58 epirubicin 58 5-FU/LV 58 alpha 2a 58 docetaxel Taxotere R 58 peginterferon alfa 2a #KD 58 patients evaluable 58 octreotide LAR 58 mesalamine granules 58 mcg QD 58 #.#g/day 58 CRp 58 induction regimen 58 gemcitabine chemotherapy 58 dose escalation trial 58 decitabine 58 ug mL 58 mg/# mg [002] 58 mg dosed twice 58 postmenopausal osteoporotic women 58 low dose cytarabine 58 naïve HCV 58 weekly subcutaneous injections 58 adriamycin 58 pegylated interferon alfa 2b 58 Gy fractions 58 cisplatin gemcitabine 58 heavily pretreated patients 58 Fludara 58 atazanavir ritonavir 57 metastatic GIST 57 μmol L 57 ACR# response 57 mg/# h 57 plasma concentrations 57 mg doses 57 plus prednisone prednisolone 57 ug dose 57 Taxotere R 57 cell lymphoma CTCL 57 dosing intervals 57 OADs 57 LANTUS R 57 HBeAg negative 57 remission induction 57 pmol L 57 peg interferon 57 oral allopurinol 57 DOXIL 57 plus dexamethasone 57 dosing regimens 57 GnRH agonist 57 thrombocytopenia 57 lispro 57 HBeAg positive patients 57 PegIFN 57 hours postdose 57 tobramycin inhalation solution 57 cells μL 57 inhalations twice 57 mg kg intravenously 57 CR CRu 57 hypokalemia 57 ceftriaxone 57 pegylated interferon 57 virologic failure 57 pegylated liposomal doxorubicin 57 ara C 57 limiting toxicity 57 cyclophosphamide methotrexate 57 etoposide 57 mg/# mg twice 57 mitoxantrone plus 57 dose cytarabine 57 mg simvastatin 57 ACTEMRA TM 57 valopicitabine 57 infliximab 57 peginterferon alfa 2a Pegasys 57 5FU 57 refractory multiple myeloma 57 oral rivaroxaban 57 QTcF 57 tipranavir r 57 Flu Cy 57 #.#mg/dL 57 ≥ 57 5mg/kg 57 Capecitabine 57 3mg 57 clodronate 57 bortezomib Velcade R 57 intradermal injections 57 pegylated interferon alpha 57 Hemopurifier ® treatments 57 LPV r 57 active comparator 57 intravenous doses 57 cytogenetic response 57 neoadjuvant 57 prior chemotherapy regimens 57 ritonavir boosted atazanavir 57 aminotransferase elevations greater 56 COPEGUS 56 dosing schedules 56 docetaxel Taxotere ® 56 darunavir ritonavir 56 cells uL 56 hypomagnesemia 56 interferon alfa 2b 56 azacitidine 56 cells/mm3 56 BEACOPP 56 dosing interval 56 HBeAg positive 56 standard chemotherapy regimen 56 hour bronchodilation 56 SVR# 56 ng dl 56 alanine aminotransferase 56 EUFLEXXA R 56 dose dexamethasone 56 topotecan 56 #mg doses [002] 56 MBq 56 mg dosed 56 tenofovir disoproxil fumarate 56 administered intravenously 56 heavily pretreated 56 mg/# hours 56 amoxicillin clavulanate 56 ceftazidime 56 free survival PFS 56 bendamustine 56 cyclophosphamide doxorubicin vincristine 56 nucleoside naive 56 kilogram mg kg 56 dasatinib Sprycel ® 56 Free Survival PFS 56 cytarabine 56 sustained virologic response 56 Response Evaluation Criteria 56 pomalidomide 56 lymphoid blast 56 8mg 56 forodesine 56 Psoriasis Area 56 safety tolerability pharmacokinetics 56 events AEs 56 mEq L 56 low dose dexamethasone 56 Cmax 56 insulin detemir 56 anthracycline taxane 56 lenalidomide 56 intravenous dosing 56 plus gemcitabine 56 #mg dose [002] 56 aspartate aminotransferase 56 rituximab 56 amprenavir 56 TMC# C# 56 neoadjuvant chemotherapy 56 copies mL 56 log# copies mL 56 hematologic toxicity 56 Median PFS 56 Dose escalation 56 Phase 1a 56 trastuzumab Herceptin R 56 serum HBV DNA 56 HIV RNA 56 PSA nadir 56 Ph + ALL 56 mg q#h 56 ALT normalization 56 degarelix 56 achieved statistical significance 56 remission CR 56 sUA 56 #mg dose [003] 56 receiving highly emetogenic 56 mg mL 56 gemcitabine carboplatin 56 potent CYP#A# inhibitors 56 Ceplene/IL-2 56 Acetate Rectal Suppositories 56 virological failure 55 telaprevir pegylated interferon 55 mitoxantrone chemotherapy 55 unresectable 55 Taxotere ® 55 HBV DNA levels 55 placebo dexamethasone 55 Chemophase 55 concurrent chemoradiation 55 metastatic colorectal carcinoma 55 nucleoside analog 55 peginterferon alpha 2a 55 pegylated alpha interferon 55 IFN alfa 55 #mg [001] 55 docetaxel Taxotere 55 tumor progression TTP 55 Solid Tumors criteria 55 PEG Interferon lambda 55 treatment naive genotype 55 epirubicin cyclophosphamide 55 azathioprine 55 endoscopic remission 55 budesonide pMDI 55 dose escalation study 55 mg FV 55 metastatic CRC 55 discontinuations due 55 advanced carcinoid 55 HGS ETR1 55 subcutaneous infusion 55 Omacetaxine mepesuccinate 55 relapsed CLL 55 daily subcutaneous injections 55 receiving INTRON 55 GEMZAR 55 SCH # 55 ABRAXANE therapy 55 REBETOL 55 oral levofloxacin 55 huN# DM1 55 mg Lucentis 55 fluorouracil leucovorin 55 golimumab CNTO 55 irbesartan 55 BENICAR HCT 55 #mg #mg #mg [003] 55 MCyR 55 cytogenetic responses 55 G CSF 55 mL kg 55 paclitaxel poliglumex 55 intravenous dose 55 HBeAg negative patients 55 Peginterferon Alfa 2a 55 bortezomib refractory 55 oxycodone CR 55 leucovorin 55 mg tid 55 neutropenia dehydration dyspnea 55 Pegasys peginterferon alfa 2a 55 undetectable virus HCV 55 virologic breakthrough 55 intramuscular dose 55 hypophosphatemia 55 flutamide 55 paclitaxel carboplatin 55 mu g 55 posaconazole 55 6mg 55 eribulin mesylate 55 5 Fluorouracil 55 zoledronic acid 55 cisplatin chemotherapy 55 gemcitabine Gemzar ® 55 nM 55 mIU mL 55 achieved sustained virologic 55 ALVESCO 55 -#.# log# 55 ribavirin therapy 55 pegfilgrastim 55 paclitaxel Taxol ® 55 STELARA 55 DAS# remission 55 ng mL 55 methotrexate therapy 55 PEG Intron ® 55 placebo p = 55 fluticasone salmeterol 55 patients receiving ERBITUX 55 lenalidomide Revlimid R 55 Copegus ribavirin 55 peginterferon 55 corticosteroid dose 55 sunitinib 55 PREZISTA rtv 55 insulin degludec 55 HCV RNA 55 IFN α 55 Phase 1b 55 prospectively defined 55 treatment naïve genotype 55 temsirolimus 55 CANCIDAS 55 creatinine clearance 55 null responder HCV 55 metastatic hormone refractory 55 paclitaxel cisplatin 55 paclitaxel Taxol R 55 intravenous IV infusion 55 ofatumumab 55 bolus injection 55 Tarceva TM 55 RECIST Response Evaluation Criteria 55 pemetrexed 55 ertapenem 55 stage IIIb IV 55 FluCAM 55 adefovir 54 elotuzumab 54 CR nPR 54 boosted protease inhibitor 54 HCV RESPOND 2 54 beta2 agonist 54 TMC# [001] 54 plasma HCV RNA 54 telaprevir VX 54 FUSILEV enhances 54 MIRCERA 54 alanine aminotransferase ALT 54 ispinesib administered 54 mycophenolate mofetil 54 fallopian tube carcinoma 54 receiving VICTRELIS 54 Allovectin 7 ® 54 cisplatin 54 nodular partial response 54 fosamprenavir 54 FOLFOX regimen 54 desvenlafaxine succinate 54 underwent surgical resection 54 HER2 positive metastatic breast 54 complete cytogenetic 54 iobenguane 54 #mg dose [001] 54 fluticasone furoate 54 rizatriptan 54 mapatumumab 54 dexamethasone Decadron 54 CLL SLL 54 pyrimidine nucleoside analog 54 doxorubicin docetaxel 54 #/#.# mcg 54 fludarabine cyclophosphamide 54 μg mL 54 uM 54 Engerix B 54 TDF FTC 54 postdose 54 detectable HCV RNA 54 generalized edema 54 mcg linaclotide 54 postoperative chemotherapy 54 ibandronate 54 dosing 54 CLARITY study 54 Telintra 54 placebo 54 EMEND 54 highly emetogenic 54 PEGINTRON TM 54 Doxil ® 54 lumbar spine BMD 54 1mg 54 5 FU leucovorin 54 Peginterferon 54 neurologic progression 54 PEG Intron 54 lymphocytosis 54 rifapentine 54 randomized 54 oral prodrug 54 FIRMAGON 54 oblimersen 54 neutrophil count 54 dosed 54 epoetin alpha 54 leukopenia 54 Traficet EN 54 efavirenz EFV 54 PROMACTA 54 Elitek 54 iniparib BSI 54 ALT elevations 54 Panzem R NCD 54 lintuzumab SGN 54 CIMZIA ™ 54 gemcitabine cisplatin 54 mesalamine 54 evaluating tivozanib 54 IXEMPRA 54 steroid dexamethasone 54 BENICAR 54 oral clodronate 54 dosing regimen 54 Forodesine HCl 54 cEVR 54 pharmacokinetic parameters 54 randomized #:#:# 54 PegIFN RBV 54 bronchodilation 54 urinary N telopeptide 54 chemotherapy docetaxel 54 Phase Ib clinical trials 54 Pegasys R 54 FFNS 54 nasal spray inhaled 54 relapsed multiple myeloma 54 mM 54 histologically confirmed 54 tanespimycin 54 pyrazinamide 54 LEXIVA 54 platinum refractory 54 PSMA ADC 54 EURIDIS 54 serum HCV RNA 54 milligrams mg 54 galiximab 54 gout flares 54 chemotherapy regimens 54 Pharmacokinetic parameters 54 kg -1 54 sorafenib Nexavar 54 CDAI 54 EGFR TKI 54 spontaneous bowel movements 54 alefacept 54 alvespimycin 54 lymphopenia 54 ACR# responses 54 RGT arm 54 MIC# [001] 54 glufosfamide 54 HCV SPRINT 54 Index CDAI score 54 leukemia AML 54 lamivudine 54 unresectable Stage III 54 sorafenib Nexavar ® 54 lactate dehydrogenase 54 IIIa inhibitor 54 visilizumab 54 AGILECT R 54 trastuzumab 54 DAVANAT 53 splenectomized patients 53 peginterferon alfa 53 log# reduction 53 ULORIC 53 Solid Tumors RECIST 53 pegylated interferon alfa 53 ABC/3TC 53 sorafenib tablets 53 locoregional 53 Elotuzumab 53 Contrave# 53 capecitabine 53 nonmyeloablative 53 refractory chronic lymphocytic 53 Melphalan 53 rapid virological response 53 serum phosphorus 53 mg subcutaneous 53 SPRYCEL 53 intravenous infusions 53 bevacizumab 53 evaluating Xcytrin 53 dose escalation phase 53 Lupuzor ™ 53 hypofractionated 53 fallopian tube cancers 53 abiraterone acetate 53 TORISEL 53 dose cyclophosphamide 53 CTA# Injection 53 irinotecan doxorubicin oxaliplatin paclitaxel 53 infliximab monotherapy 53 mucosal healing 53 demonstrated antitumor activity 53 certolizumab pegol 53 nucleoside naive patients 53 BARACLUDE ® 53 Gemcitabine 53 maximally tolerated dose 53 Navelbine 53 administered intradermally 53 vandetanib 53 achieved CCyR 53 oral ribavirin 53 PEGINTRON 53 liposomal formulation 53 antithymocyte globulin 53 cisplatin vinorelbine 53 tacrolimus 53 Aflibercept 53 adjunctive placebo 53 serum concentrations 53 erlotinib Tarceva ® 53 PEG Interferon alfa 53 Solid Tumors 53 undetectable HBV DNA 53 imatinib 53 Toxicities 53 tolterodine ER 53 FOLFIRI alone 53 Pemetrexed 53 TMC# r 53 doxorubicin HCl liposome injection 53 cytotoxic chemotherapy 53 elevated transaminases 53 dependent kinase inhibitor 53 chemoradiotherapy 53 placebo PBO 53 LIALDA 53 dose regimen 53 HGS ETR2 53 â ‰ ¥ 53 hypercalcemia 53 hematologic adverse 53 refractory AML 53 Decitabine 53 papillary renal cell carcinoma 53 EQUATE OB 53 pegIFN 53 autoantibody positive 53 chemoradiation therapy 53 tipranavir 53 inhaled fluticasone 53 DAPT 53 triptorelin 53 NovoLog ® Mix 53 log# IU mL 53 ethambutol 53 virologic response 53 IMGN# 53 triamcinolone 53 tolvaptan 53 irinotecan containing 53 azilsartan medoxomil 53 SPRYCEL ® 53 % Confidence Interval 53 HCV genotypes 53 composite endpoint 53 salmeterol fluticasone 53 Scale EDSS 53 alanine transaminase ALT 53 6 mercaptopurine 53 plus COPEGUS 53 blinded randomized 53 Secondary endpoints include 53 tinzaparin 53 adecatumumab 53 inhaled tobramycin 53 laboratory abnormalities 53 rituximab Rituxan ® 53 1mg 2mg 53 advanced unresectable 53 Indacaterol 53 SCIg 53 sorafenib 53 budesonide formoterol 53 favorable pharmacokinetic profile 53 Trial Evaluating 53 dasatinib 53 antiretroviral naive 53 BRIM2 53 dacarbazine DTIC 53 Zometa hazard 53 thymalfasin 53 COZAAR 53 metastatic RCC 53 mRCC 53 tirofiban 53 beclomethasone dipropionate 53 recurrent NSCLC 53 AzaSite Plus 53 tapentadol ER 53 g dL 53 anthracyclines taxanes 53 ng ml 53 PSADT 53 intravesical 53 serum urate 53 miconazole 53 nausea dehydration dyspnea 53 HCV genotype 53 Paraplatin ® 53 3TC lamivudine Epivir 53 ribavirin 53 Aptivus ® 53 PREZISTA r arm 53 recurrent glioblastoma multiforme 53 mg p = 53 Irinotecan 53 chemotherapy cisplatin 53 mg calcium 53 KOMBIGLYZE XR 53 distant metastases 53 administered intramuscularly 53 μg ml 53 dose colchicine 53 Laquinimod 53 PRECiSE 53 tocilizumab 53 biologic DMARD 53 milligram doses 53 hematologic 53 mU liter 53 recurrent genital herpes 53 EDEMA4 trial 53 oral dosing 53 XELOX 53 LAB GHRH 53 double blinded placebo 53 pg ml 53 DMARD therapy 53 Platinol ® 53 goserelin 52 Initiate Phase 52 distant metastasis 52 receptor tyrosine kinase inhibitor 52 #ug [002] 52 irinotecan 52 virologic response EVR 52 systemic ALCL 52 APTIVUS 52 lopinavir ritonavir Kaletra 52 pegylated interferon alpha 2a 52 protease inhibitor PI 52 metastatic castration resistant 52 NEXIUM 52 placebo controlled Phase 52 Index CDAI 52 GSK# [001] 52 copies ml 52 liposomal doxorubicin 52 advanced hepatocellular carcinoma 52 p = NS 52 primary hypercholesterolemia 52 temozolomide 52 Omacetaxine 52 Gy 52 tenofovir emtricitabine 52 refractory CTCL 52 imetelstat 52 fluconazole 52 APRISO 52 nicardipine 52 dose dose escalation 52 alkylating agent 52 neoadjuvant treatment 52 paclitaxel chemotherapy 52 nelfinavir 52 glargine 52 pharmacodynamic profile 52 oral ibandronate 52 refractory CLL 52 refractory cutaneous T 52 tiotropium 52 limiting toxicity DLT 52 apremilast 52 luteinizing hormone releasing 52 hyperphenylalaninemia HPA due 52 multicenter Phase 52 docetaxel prednisone 52 unresectable stage 52 fumarate 52 linezolid 52 micrograms mcg 52 neutropenia 52 alfa 2b 52 #mg ritonavir 52 Vicinium TM 52 bupivacaine 52 elevated ALT 52 concentration Cmax 52 ULN 52 celgosivir 52 leuprorelin 52 imatinib therapy 52 2mg 52 PEGylated anti 52 nitazoxanide 52 rHuPH# 52 huC# DM4 52 fluoropyrimidine 52 RECIST 52 genotypic resistance 52 metastatic renal cell carcinoma 52 HES CEL 52 motesanib 52 baseline LDH 52 radiochemotherapy 52 cells mcL 52 EBRT 52 lanreotide 52 Bortezomib 52 QTc 52 valacyclovir 52 serum phosphate 52 Alkeran 52 non splenectomized 52 Sandostatin ® 52 paclitaxel 52 ^ sup 52 ISTODAX 52 YONDELIS 52 ABVD 52 Pharmacokinetics PK 52 TTF Therapy 52 mm3 52 topical gel formulation 52 response CCyR 52 chronic HCV genotype 52 serum testosterone 52 deferoxamine 52 μM 52 budesonide foam 52 aspartate aminotransferase AST 52 lanthanum carbonate 52 cART 52 chemo radiotherapy 52 lymphoid malignancies 52 doripenem 52 octreotide 52 oral deforolimus 52 interferon ribavirin 52 trough FEV1 52 #mg ATC 52 tipranavir ritonavir 52 null responders 52 acute GvHD 52 glatiramer acetate 52 cyclophosphamide AC 52 ongoing Phase 1b 52 definite stent thrombosis 52 Anti TNF 52 IV NSCLC 52 budesonide 52 atazanavir 52 mcg kg min 52 NRTIs 52 glulisine 52 venlafaxine ER 52 complete remissions 52 vincristine doxorubicin 52 fraction LVEF 52 plus OBT 52 cyclophosphamide Cytoxan 52 Aclidinium 52 tolerability 52 HuMax CD4 52 TYGACIL 52 Viread Emtriva 52 unfractionated heparin 52 lamivudine refractory patients 52 edoxaban 52 AEGR 52 AUC0 52 HCV genotype 1 52 zoledronate 52 nevirapine NVP 52 blood Phe 52 NATRECOR R 52 insulin glulisine 52 hepatic metastases 52 intravenously administered 52 novel VDA molecule 52 seroprotection 52 epirubicin cisplatin 52 oral ridaforolimus 52 #:# randomization 52 detemir 52 Xeloda ® 52 5 FU 52 teriflunomide 52 ARCOXIA 52 sitagliptin 52 TMC# [002] 52 bolus dose